H.R. 2085 · 113th Congress
Diagnostic Innovation Testing and Knowledge Advancement Act of 2013
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 113th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
RoskamSponsor24 cosponsors · 7 D, 17 R
R
Guthrie
RK
D
Kind
LL
R
Lance
RN
D
Neal
EP
R
Paulsen
PT
R
Tiberi
LB
R
Bucshon
AS
R
Schock
TG
R
Griffin
KY
R
Yoder
BS
D
Schneider
MK
R
Kelly
TR
R
Rokita
DH
D
Heck
PS
R
Sessions
PW
D
Welch
BL
D
Luján
TL
R
Latham
AK
R
Kinzinger
RD
R
Davis
MS
R
Stutzman
CG
R
Gardner
TD
D
Duckworth
RH
R
Hultgren6 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Diagnostic Innovation Testing and Knowledge Advancement Act of 2013 - Sets forth additional factors for the Secretary of Health and Human Services (HHS) to consider in determining the payment amount for new clinical diagnostic laboratory tests under gapfilling procedures which are used when no comparable existing test is available.
What it does: CRS summary · Introduced in House · May 22, 2013
Diagnostic Innovation Testing and Knowledge Advancement Act of 2013 - Sets forth additional factors for the Secretary of Health and Human Services (HHS) to consider in determining the payment amount for new clinical diagnostic laboratory tests under gapfilling procedures which are used when no comparable existing test is available.
Directs the Secretary to convene an independent advisory panel to inform and make recommendations to the Secretary regarding any new test.
Requires the Secretary to justify publicly the basis and rate determination for any payments made under the clinical laboratory fee schedule for new clinical diagnostic laboratory tests, including a detailed summary of information received regarding the additional factors considered.
Requires the Secretary then, after publishing such justification, to provide for a reasonable period of reconsideration to: (1) receive any appeal of the payment determination, and (2) evaluate any additional information received regarding the justification and the factors considered.
Requires the Secretary, following the period of reconsideration, to make a final payment basis and payment rate determination, providing a justification for it with an explanation of what additional information was evaluated during reconsideration and how it was taken into account.
Directs the Secretary to: (1) establish a process for application for the assignment of a temporary national HCPCS (Healthcare Common Procedure Coding System) code to uniquely identify a diagnostic test until a permanent national HCPCS code is available for assignment to that test, (2) analyze the process used for the gapfilling procedures used in determining payment amounts for new clinical diagnostic laboratory tests, and (3) implement improvements in the process after public notice and opportunity for comment.
Applies this Act to payment basis and payment rate determinations made on or after January 1, 2013.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Diagnostic Innovation Testing and Knowledge Advancement Act of 2013
Latest action (Jun 3, 2013): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: May 22, 2013
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.